• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺腺癌中表皮生长因子受体 19 号和 21 号外显子突变与影像学和临床特征的关系。

Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma.

机构信息

Department of Radiology, Changhai Hospital, Second Military Medical University, Shanghai, China.

Clinical Nutrition Department, Changhai Hospital, Second Military Medical University, Shanghai, China.

出版信息

Sci Rep. 2017 Mar 23;7(1):364. doi: 10.1038/s41598-017-00511-2.

DOI:10.1038/s41598-017-00511-2
PMID:28336963
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5428650/
Abstract

The exon 19 and 21 in Epidermal Growth Factor Receptor (EGFR) mutation are the most common subtype of lung adenocarcinoma, and the strongest predictive biomarker for progression-free survival and tumor response. Although some studies have shown differences in radiological features between cases with and without EFGR mutations, they lacked necessary stratification. This article is to evaluate the association of CT features between the wild type and the subtype (exon 19 and 21) of EGFR mutations in patients with lung adenocarcinoma. Of the 721 finally included patients, 132 were positive for EGFR mutation in exon 19, 140 were positive for EGFR mutation in exon 21, and 449 were EGFR wild type. EGFR mutation in exon 19 was associated with a small-maximum diameter (28.51 ± 14.07) (p < 0.0001); sex (p < 0.0001); pleural retraction (p = 0.0034); and the absence of fibrosis (p < 0.0001), while spiculated margins (p = 0.0095), subsolid density (p < 0.0001) and no smoking (p < 0.0001) were associated with EGFR mutation in exon 21. Receiver Operating Characteristic (ROC) curves suggested that the maximum Area Under the Curve (AUC) was related to the female gender (AUC = 0.636) and the absence of smoking (AUC = 0.681). This study demonstrated the radiological and clinical features could be used to prognosticate EGFR mutation subtypes in exon 19 and 21.

摘要

表皮生长因子受体(EGFR)exon19 和 21 突变是肺腺癌最常见的亚型,也是无进展生存期和肿瘤反应的最强预测生物标志物。虽然一些研究表明 EGFR 突变与无 EGFR 突变病例的影像学特征存在差异,但这些研究缺乏必要的分层。本文旨在评估肺腺癌患者 EGFR 野生型和突变型(exon19 和 21)的 CT 特征之间的关联。最终纳入的 721 例患者中,exon19 突变 EGFR 阳性 132 例,exon21 突变 EGFR 阳性 140 例,EGFR 野生型 449 例。exon19 突变与小-最大直径(28.51±14.07)(p<0.0001)、性别(p<0.0001)、胸膜回缩(p=0.0034)、无纤维化(p<0.0001)有关,而分叶状边缘(p=0.0095)、亚实性密度(p<0.0001)和不吸烟(p<0.0001)与 exon21 突变有关。受试者工作特征(ROC)曲线提示,最大曲线下面积(AUC)与女性性别(AUC=0.636)和不吸烟(AUC=0.681)有关。本研究表明,影像学和临床特征可用于预测 exon19 和 21 中的 EGFR 突变亚型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fd8/5428650/7ba25d5dcc39/41598_2017_511_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fd8/5428650/6b7754b61dd7/41598_2017_511_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fd8/5428650/afc3b5fbaf67/41598_2017_511_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fd8/5428650/72905620d3c3/41598_2017_511_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fd8/5428650/c882ea7c2e0a/41598_2017_511_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fd8/5428650/7ba25d5dcc39/41598_2017_511_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fd8/5428650/6b7754b61dd7/41598_2017_511_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fd8/5428650/afc3b5fbaf67/41598_2017_511_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fd8/5428650/72905620d3c3/41598_2017_511_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fd8/5428650/c882ea7c2e0a/41598_2017_511_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fd8/5428650/7ba25d5dcc39/41598_2017_511_Fig5_HTML.jpg

相似文献

1
Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma.肺腺癌中表皮生长因子受体 19 号和 21 号外显子突变与影像学和临床特征的关系。
Sci Rep. 2017 Mar 23;7(1):364. doi: 10.1038/s41598-017-00511-2.
2
Clinicoradiological features associated with epidermal growth factor receptor exon 19 and 21 mutation in lung adenocarcinoma.肺腺癌中与表皮生长因子受体外显子 19 和 21 突变相关的临床放射学特征。
Clin Radiol. 2019 Jan;74(1):80.e7-80.e17. doi: 10.1016/j.crad.2018.10.001. Epub 2018 Oct 26.
3
Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma.肺腺癌表皮生长因子受体突变患者的临床数据与计算机断层扫描特征之间的相关性。
Int J Clin Oncol. 2018 Apr;23(2):249-257. doi: 10.1007/s10147-017-1197-8. Epub 2017 Oct 7.
4
Score for lung adenocarcinoma in China with EGFR mutation of exon 19: Combination of clinical and radiological characteristics analysis.中国19外显子表皮生长因子受体(EGFR)突变肺腺癌的评分:临床与影像学特征分析的结合
Medicine (Baltimore). 2018 Sep;97(38):e12537. doi: 10.1097/MD.0000000000012537.
5
CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.肺腺癌患者中与表皮生长因子受体突变状态相关的CT特征
Radiology. 2016 Jul;280(1):271-80. doi: 10.1148/radiol.2016151455. Epub 2016 Mar 3.
6
Computed Tomography-Based Radiomics Signature: A Potential Indicator of Epidermal Growth Factor Receptor Mutation in Pulmonary Adenocarcinoma Appearing as a Subsolid Nodule.基于计算机断层扫描的放射组学特征:一种潜在的肺腺癌实体性结节中表皮生长因子受体突变的指标。
Oncologist. 2019 Nov;24(11):e1156-e1164. doi: 10.1634/theoncologist.2018-0706. Epub 2019 Apr 1.
7
CT Gray-Level Texture Analysis as a Quantitative Imaging Biomarker of Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma of the Lung.CT灰度纹理分析作为肺腺癌表皮生长因子受体突变状态的定量成像生物标志物
AJR Am J Roentgenol. 2015 Nov;205(5):1016-25. doi: 10.2214/AJR.14.14147.
8
Imaging-Based Surrogate Markers of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma: A Local Perspective.基于影像学的肺腺癌表皮生长因子受体突变的替代标志物:局部观点。
Can Assoc Radiol J. 2020 May;71(2):208-216. doi: 10.1177/0846537119888387. Epub 2020 Jan 27.
9
Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes.具有表皮生长因子受体突变的肺腺癌的放射基因组相关性:影像学特征和组织学亚型
Eur Radiol. 2016 Oct;26(10):3660-8. doi: 10.1007/s00330-015-4196-z. Epub 2016 Jan 19.
10
Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma.计算机断层扫描与表皮生长因子受体突变状态相关的临床特征在 I/II 期肺腺癌。
Thorac Cancer. 2017 May;8(3):260-270. doi: 10.1111/1759-7714.12436. Epub 2017 Apr 6.

引用本文的文献

1
The differential prognostic implications of PD-L1 expression in the outcomes of Filipinos with -mutant NSCLC treated with tyrosine kinase inhibitors.PD-L1表达对接受酪氨酸激酶抑制剂治疗的菲律宾KRAS突变型非小细胞肺癌患者预后的差异影响。
Transl Lung Cancer Res. 2023 Sep 28;12(9):1896-1911. doi: 10.21037/tlcr-23-118. Epub 2023 Aug 23.
2
Using combined CT-clinical radiomics models to identify epidermal growth factor receptor mutation subtypes in lung adenocarcinoma.使用联合CT-临床影像组学模型识别肺腺癌中的表皮生长因子受体突变亚型。
Front Oncol. 2022 Aug 18;12:846589. doi: 10.3389/fonc.2022.846589. eCollection 2022.
3

本文引用的文献

1
Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.非小细胞肺癌中体细胞突变与代谢成像表型之间的关联
J Nucl Med. 2017 Apr;58(4):569-576. doi: 10.2967/jnumed.116.181826. Epub 2016 Sep 29.
2
Predicting EGFR mutation status in lung cancer:Proposal for a scoring model using imaging and demographic characteristics.预测肺癌中的表皮生长因子受体(EGFR)突变状态:一项使用影像学和人口统计学特征的评分模型提案
Eur Radiol. 2016 Nov;26(11):4141-4147. doi: 10.1007/s00330-016-4252-3. Epub 2016 Mar 30.
3
Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas.
Clinical and Radiological Characteristics to Differentiate Between EGFR Exon 21 and Exon 19 Mutations in Patients With Lung Adenocarcinoma: A Systematic Literature Review and Meta-Analysis.
鉴别肺腺癌患者表皮生长因子受体(EGFR)第21外显子和第19外显子突变的临床及影像学特征:一项系统文献综述与荟萃分析
Cureus. 2022 May 29;14(5):e25446. doi: 10.7759/cureus.25446. eCollection 2022 May.
4
Development and externally validate MRI-based nomogram to assess EGFR and T790M mutations in patients with metastatic lung adenocarcinoma.开发并外部验证基于 MRI 的列线图,以评估转移性肺腺癌患者的 EGFR 和 T790M 突变。
Eur Radiol. 2022 Oct;32(10):6739-6751. doi: 10.1007/s00330-022-08955-5. Epub 2022 Jun 22.
5
Machine Learning-Based Radiomics for Prediction of Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma.基于机器学习的放射组学预测肺腺癌表皮生长因子受体突变。
Dis Markers. 2022 May 7;2022:2056837. doi: 10.1155/2022/2056837. eCollection 2022.
6
Establishment and Evaluation of EGFR Mutation Prediction Model Based on Tumor Markers and CT Features in NSCLC.基于肿瘤标志物和 CT 特征的 NSCLC 中 EGFR 突变预测模型的建立与评估。
J Healthc Eng. 2022 Apr 5;2022:8089750. doi: 10.1155/2022/8089750. eCollection 2022.
7
Clinical and CT patterns to predict EGFR mutation in patients with non-small cell lung cancer: A systematic literature review and meta-analysis.预测非小细胞肺癌患者表皮生长因子受体突变的临床和CT模式:一项系统文献综述与荟萃分析
Eur J Radiol Open. 2022 Feb 7;9:100400. doi: 10.1016/j.ejro.2022.100400. eCollection 2022.
8
Radiomic Feature-Based Nomogram: A Novel Technique to Predict EGFR-Activating Mutations for EGFR Tyrosin Kinase Inhibitor Therapy.基于影像组学特征的列线图:一种预测表皮生长因子受体激活突变以指导表皮生长因子受体酪氨酸激酶抑制剂治疗的新技术。
Front Oncol. 2021 Aug 6;11:590937. doi: 10.3389/fonc.2021.590937. eCollection 2021.
9
Identification of a novel prognostic DNA methylation signature for lung adenocarcinoma based on consensus clustering method.基于共识聚类方法鉴定肺腺癌的新型预后 DNA 甲基化标志物。
Cancer Med. 2020 Oct;9(20):7488-7502. doi: 10.1002/cam4.3343. Epub 2020 Aug 28.
10
Value of combining PET/CT and clinicopathological features in predicting EGFR mutation in Lung Adenocarcinoma with Bone Metastasis.PET/CT与临床病理特征相结合在预测肺腺癌骨转移患者表皮生长因子受体(EGFR)突变中的价值
J Cancer. 2020 Jul 11;11(18):5511-5517. doi: 10.7150/jca.46414. eCollection 2020.
放射组学特征与肺腺癌中的表皮生长因子受体(EGFR)突变状态相关。
Clin Lung Cancer. 2016 Sep;17(5):441-448.e6. doi: 10.1016/j.cllc.2016.02.001. Epub 2016 Feb 16.
4
CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.肺腺癌患者中与表皮生长因子受体突变状态相关的CT特征
Radiology. 2016 Jul;280(1):271-80. doi: 10.1148/radiol.2016151455. Epub 2016 Mar 3.
5
Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.酪氨酸激酶抑制剂治疗后携带表皮生长因子受体第19外显子或第21外显子突变的非小细胞肺癌患者临床结局的比较:一项荟萃分析
Eur J Clin Pharmacol. 2016 Jan;72(1):1-11. doi: 10.1007/s00228-015-1966-0.
6
Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.《2015年世界卫生组织肺、胸膜、胸腺和心脏肿瘤分类》简介
J Thorac Oncol. 2015 Sep;10(9):1240-1242. doi: 10.1097/JTO.0000000000000663.
7
Genomic alterations in lung adenocarcinoma.肺腺癌中的基因组改变。
Lancet Oncol. 2015 Jul;16(7):e342-51. doi: 10.1016/S1470-2045(15)00077-7.
8
CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.非小细胞肺癌中EGFR、K-RAS和ALK突变的CT放射基因组学特征
Eur Radiol. 2016 Jan;26(1):32-42. doi: 10.1007/s00330-015-3814-0. Epub 2015 May 9.
9
Detection of EGFR-TK domain-activating mutations in NSCLC with generic PCR-based methods.用基于通用聚合酶链反应的方法检测非小细胞肺癌中表皮生长因子受体酪氨酸激酶结构域激活突变
Appl Immunohistochem Mol Morphol. 2015 Mar;23(3):163-71. doi: 10.1097/PDM.0000000000000035.
10
Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations.肺腺癌中具有 ALK 重排或 EGFR 突变的临床放射学特征的对比分析。
Eur Radiol. 2015 May;25(5):1257-66. doi: 10.1007/s00330-014-3516-z. Epub 2015 Jan 11.